Hangzhou Hanx Biopharmaceuticals, Ltd.
Clinical trials sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd., explained in plain language.
-
New Dual-Action antibody shows promise in advanced cancer trial
Disease control CompletedThis study tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. The main g…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New Dual-Action antibody shows promise for tough lymphoma cases
Disease control CompletedThis early-phase trial tested a new drug called HX009 in 48 adults with lymphoma that returned or didn't respond to prior treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help cancer hide from the immune system. The goal was to see …
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC